North America Cell and Gene Therapy CDMO Market Size, Share By Service Area (Cell Therapy, Plasmid DNA, Viral Vector, and Others), By Indication (Cancer, Cardiovascular Disease, Infectious Disease, Genetic Disorders, Neurological Disorders), By Phase (Phase 1, Phase 2, Phase 3, Phase 4) and By Country - Trends, Analysis, and Forecast till 2034

Report Code: PMI542324 | Publish Date: July 2024 | No. of Pages: 148

North America Cell And Gene Therapy Cdmo Market Overview

North America Cell and Gene Therapy CDMO Market was valued at USD 2.5 Billion in 2024 and is expected to reach USD 30.1 Billion by 2034 growing at a CAGR of 28.9%

The Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) market stands at the forefront of transformative healthcare innovations, poised to revolutionize the treatment landscape for a myriad of diseases. As the demand for personalized medicine grows and the potential of cell and gene therapies becomes increasingly evident, the role of CDMOs becomes indispensable. These organizations play a pivotal role in bridging the gap between research and commercialization, offering specialized expertise and infrastructure for the development and manufacturing of cell and gene therapies. With a focus on scalability, quality assurance, and regulatory compliance, CDMOs enable biopharmaceutical companies to bring their therapies from concept to market with efficiency and confidence. In this dynamic landscape of breakthrough therapies and evolving regulatory frameworks, the Cell and Gene Therapy CDMO market represents a nexus of innovation, collaboration, and opportunity, poised to drive transformative advancements in healthcare for years to come.

North America Cell And Gene Therapy Cdmo Market Dynamics

Key Drivers of Target Market:

The Role of Rare Diseases

The rising prevalence of genetic and rare diseases stands as a pivotal driving force propelling the growth of the Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) market. As awareness of these conditions increases, so does the demand for innovative treatments capable of addressing their underlying genetic causes. Cell and gene therapies offer promising avenues for intervention by targeting and correcting genetic abnormalities at their source, potentially providing long-term or curative benefits for patients. In response to this demand, biopharmaceutical companies are increasingly turning to CDMOs for their specialized expertise in developing and manufacturing these advanced therapies. CDMOs play a crucial role in advancing the development and commercialization of cell and gene therapies, offering end-to-end services including process development, manufacturing, and quality assurance, thereby facilitating the efficient and effective delivery of these life-changing treatments to patients in need.

Technological Advancements

A significant market driving factor for the Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) market is the continuous advancement of technology. Technological innovations play a pivotal role in enhancing the development, manufacturing, and commercialization processes of cell and gene therapies, making them more efficient, scalable, and cost-effective. Advanced technologies such as automation, high-throughput screening, gene editing tools (e.g., CRISPR-Cas9), and viral vector production systems have revolutionized various aspects of cell and gene therapy development, allowing for faster and more precise manufacturing processes. These technological advancements not only streamline production but also improve product quality, consistency, and safety. Additionally, innovative digital platforms and analytics tools enable CDMOs to optimize process parameters, monitor manufacturing workflows in real time, and ensure compliance with regulatory requirements. As a result, the integration of cutting-edge technologies empowers CDMOs to meet the growing demand for cell and gene therapies, drive innovation in the field, and ultimately accelerate the delivery of transformative treatments to patients worldwide.

Restrains:

Lack of Skilled Workforce

A notable restraining factor for the Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) market is the challenge posed by a lack of skilled workforce. The specialized nature of cell and gene therapy manufacturing requires highly trained personnel with expertise in cell biology, molecular biology, bioprocessing, and other relevant fields. However, there is a scarcity of professionals with the necessary skill sets and experience to effectively navigate the complex manufacturing processes and regulatory requirements associated with these advanced therapies. As a result, CDMOs may struggle to recruit and retain qualified talent, which can impede their ability to scale operations, meet project timelines, and maintain consistent product quality. Furthermore, the shortage of skilled workforce may lead to increased labor costs and delays in project execution, ultimately affecting the competitiveness and growth potential of CDMOs in the cell and gene therapy market. Addressing this workforce challenge through targeted training programs, collaboration with academic institutions, and talent development initiatives is crucial for overcoming this restraining factor and unlocking the full potential of the cell and gene therapy CDMO market.

North America Cell And Gene Therapy Cdmo Market Segmentation

The market is segmented based on Service Area, Indication, Phase and Country.

North America Cell and Gene Therapy CDMO Market Report Scope:

Attribute

Details

Market Size 2024

USD 2.5 Billion

Projected Market Size 2034

USD 30.1 Billion

CAGR Growth Rate

28.9%

Base year for estimation

2023

Forecast period

2024 – 2034

Market representation

Revenue in USD Billion & CAGR from 2024 to 2034

Market Segmentation

By Service Area - Cell Therapy, Plasmid DNA, Viral Vector, and Others

By Indication - Cancer, Cardiovascular Disease, Infectious Disease, Genetic Disorders, Neurological Disorders

By Phase - Phase 1, Phase 2, Phase 3, Phase 4

Report coverage

Revenue forecast, company share, competitive landscape, growth factors, and trends

Segments Covered in the Report:

This report forecasts revenue growth at regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2023 to 2034. For the purpose of this study segmented the North America Cell and Gene Therapy CDMO Market report based on Service Area, Indication, Phases and Country:

Segmentation:

By Service Area:

  • Cell Therapy
  • Plasmid DNA
  • Viral Vector
  • Others    

By Indication:

  • Cancer
  • Cardiovascular Disease
  • Infectious Disease
  • Genetic Disorders
  • Neurological Disorders

By Phases:

  • Phase 1
  • Phase 2
  • Phase 3
  • Phase 4

By Country:

  • U.S.
  • Canada

North America Cell And Gene Therapy Cdmo Market Key Players

The key players operating the North America Cell and Gene Therapy CDMO Market includes Catalent Inc., LONZA GROUP, RECIPHARM AB, Wuxi Advanced Therapies, Pfizer CentreOne, Charles River Laboratories International Inc., PATHEON INC., Almac Group, and FUJIFILM DIOSYNTH BIOTECHNOLOGIES, PCI Pharma Services.

North America Cell And Gene Therapy Cdmo Market Company Profile

  • Catalent Inc. *
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • LONZA GROUP
  • RECIPHARM AB
  • Wuxi Advanced Therapies
  • Pfizer CentreOne
  • Charles River Laboratories International Inc.
  • PATHEON INC., INC.
  • Almac Group
  • FUJIFILM DIOSYNTH BIOTECHNOLOGIES
  • PCI Pharma Services

“*” marked represents similar segmentation in other categories in the respective section.

North America Cell And Gene Therapy Cdmo Market Table of Contents

Research Objective and Assumption

  • Research Objectives
  • Assumptions
  • Abbreviations

Market Preview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Service Area
    • Market Snippet, By Indication
    • Market Snippet, By Phase
    • Market Snippet, By Country
  • Opportunity Map Analysis

Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Market Trends
  • Product Launch
  • Merger and Acquisitions
  • Impact Analysis
  • PEST Analysis
  • Porter’s Analysis

Market Segmentation, By Service Area, Forecast Period up to 10 Years, (USD Bn)

  • Overview
    • Market Value and Forecast (USD Bn), and Share Analysis (%), Forecast Period up to 10 Years
    • Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
    • Segment Trends
  • Cell Therapy
    • Overview
    • Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
  • Plasmid DNA-
    • Overview
    • Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
  • Viral Vector
    • Overview
    • Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
  • Others
    • Overview
    • Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years

Market Segmentation, Indication, Forecast Period up to 10 Years, (USD Bn)

  • Overview
    • Market Value and Forecast (USD Bn), and Share Analysis (%), Forecast Period up to 10 Years
    • Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
    • Segment Trends
  • Cancer
    • Overview
    • Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
  • Cardiovascular Disease
    • Overview
    • Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
  • Infectious Disease
    • Overview
    • Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
  • Genetic Disorders
    • Overview
    • Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
  • Neurological Disorders
    • Overview
    • Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years

Market Segmentation, By Country, Forecast Period up to 10 Years, (USD Bn)

  • Overview
    • Market Value and Forecast (USD Bn), and Share Analysis (%), Forecast Period up to 10 Years
    • Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
    • Country Trends
  • North America
    • Market Size and Forecast (USD Bn), By Sports Type, Forecast Period up to 10 Years
    • Market Size and Forecast (USD Bn), By Capacity, Forecast Period up to 10 Years
    • Market Size and Forecast (USD Bn), By Management, Forecast Period up to 10 Years
    • Market Size and Forecast (USD Bn), By End User, Forecast Period up to 10 Years
    • Market Size and Forecast (USD Bn), By Country, Forecast Period up to 10 Years
      • U.S.
      • Canada

 

Competitive Landscape

  • Heat Map Analysis
  • Company Profiles
    • Catalent Inc.
    • LONZA GROUP
    • RECIPHARM AB
    • Wuxi Advanced Therapies
    • Pfizer CentreOne
    • Charles River Laboratories International Inc.
    • Patheon Inc., Inc.
    • Almac Group
    • FUJIFILM DIOSYNTH BIOTECHNOLOGIES
    • PCI Pharma Services

The Last Word

  • Future Impact
  • About Us
  • Contact

FAQs

North America Cell and Gene Therapy CDMO Market is segmented into Service Area, Indication, Phase, and Country.

The role of rare diseases and technology advancement.

By Country, the North America Cell and Gene Therapy CDMO Market is segmented into the U.S. and Canada, The U.S. is expected to dominate the market due to an increase in Investment in Research.

The key players operating the North America Cell and Gene Therapy CDMO Market include Catalent Inc., LONZA GROUP, RECIPHARM AB, Wuxi Advanced Therapies, Pfizer CentreOne, Charles River Laboratories International Inc., PATHEON INC., INC., Almac Group, FUJIFILM DIOSYNTH BIOTECHNOLOGIES, PCI Pharma Services